title: [Beginning rheumatoid arthritis revealed during bronchiectasis surinfections. Value of cyclic antibiotherapy?].
abstract: Incidence of symptomatic bronchiectasis (BR) occurs in around 2% in patients with late rheumatoid arthritis (RA). Its seems that the association BR-RA could be a worsening factor for outcome of RA patients. A 58-year-old woman without dry syndrome, suffering from bronchial purulence over one year was admitted to the Department of Pneumology for hemoptysis and arthritis (knees, ankles, and wrists). Three prior episodes of inflammatory articular pain had occurred after transient bronchial purulence or pneumonitis. CT-scan showed bilateral bronchiectasis. Diagnosis of early RA was proved after the third episode of bronchial purulence related to a strain of Haemophilus influenzae. A strain of Coxiella burnetii was probably responsible for one of the three bronchial surinfections. Latex and Waaler Rose tests were transiently positive during the first episode, and became positive after the third one. At that time, RA was relevant in view of ARA criteria. Cyclic prophylactic antibiotic regimens could be proposed to patients suffering from RA-BR association, in contrast to the cases of patients with isolated BR. This approach could prevent destabilization of RA and reinforce of anti-rheumatic therapy. Activation and release of cytokines (NFk-B, TNF-alpha), and/or bacterial epitopes seems to be directly responsible for the articular destabilization.
authors.affiliation: INSERM EMI-U 00-10, Groupe de Biochimie, Faculté de Médecine, F-37032 Tours, France.
authors.forename: S
authors.initials: S
authors.lastname: Attucci
authors.forename: F
authors.initials: F
authors.lastname: Maillot
authors.forename: D
authors.initials: D
authors.lastname: Degenne
authors.forename: L
authors.initials: L
authors.lastname: Brunereau
authors.forename: P
authors.initials: P
authors.lastname: Dreyfuss
authors.forename: E
authors.initials: E
authors.lastname: Lemarie
authors.forename: E
authors.initials: E
authors.lastname: Hazouard
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000175:diagnosis* / Q000276:immunology; D001784:Blood Gas Analysis; D001987:Bronchiectasis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D016207:Cytokines / Q000187:drug effects / Q000276:immunology; D004334:Drug Administration Schedule; D005260:Female; D006192:Haemophilus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D006193:Haemophilus influenzae; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D011237:Predictive Value of Tests; D012008:Recurrence; D012129:Respiratory Function Tests; D015163:Superinfection / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D013492:Suppuration; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines